Cary Street Partners Investment Advisory LLC Gilead Sciences, Inc. Transaction History
Cary Street Partners Investment Advisory LLC
- $2.63 Billion
- Q3 2024
A detailed history of Cary Street Partners Investment Advisory LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cary Street Partners Investment Advisory LLC holds 6,969 shares of GILD stock, worth $625,537. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,969
Previous 6,979
0.14%
Holding current value
$625,537
Previous $478,000
22.18%
% of portfolio
0.02%
Previous 0.02%
Shares
13 transactions
Others Institutions Holding GILD
# of Institutions
1,924Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$10.8 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.4 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$6.87 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.55 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.4 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $113B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...